Provider Briefing: The Asmanex Supply Situation in 2026

The supply constraints affecting Asmanex (mometasone furoate) represent another chapter in the ongoing disruption to the inhaled corticosteroid (ICS) market. For prescribers managing panels of asthma patients, understanding the scope of this shortage — and having a clear substitution strategy — is essential to maintaining asthma control and preventing acute exacerbations.

This article provides a concise clinical overview of the Asmanex shortage, its causes, the affected formulations, recommended therapeutic alternatives, and practical tools to help your patients maintain medication access.

Timeline of the Asmanex Shortage

The Asmanex shortage didn't happen in isolation. It's directly connected to the broader upheaval in the ICS market that began in late 2023:

• Late 2023: GlaxoSmithKline discontinues Flovent HFA and Flovent Diskus — two of the highest-volume ICS products in the U.S. market. Millions of patients are displaced.
• Early 2024: Demand surges for remaining branded ICS products, including Asmanex, QVAR RediHaler, and Arnuity Ellipta. Organon reports increased demand for both Asmanex Twisthaler and Asmanex HFA.
• Mid-2024: ASHP lists mometasone furoate oral inhalers on its active drug shortage list. Organon places Asmanex HFA 50 mcg and 100 mcg on back order.
• Late 2025: Reports emerge that Organon may be phasing out certain Asmanex Twisthaler presentations. The 220 mcg/30-dose Twisthaler is reportedly slated for discontinuation in early 2026.
• Early 2026: Supply remains intermittent. Asmanex HFA 200 mcg and Twisthaler 110 mcg have better availability, but regional shortages persist.

Prescribing Implications

The shortage and potential product line changes have several implications for clinical practice:

Formulation-Specific Considerations

• Twisthaler vs. HFA: If a patient is currently on the Twisthaler and that formulation becomes unavailable, the Asmanex HFA is not a direct 1:1 substitution — dosing differs between the dry powder and aerosol formulations. Dose equivalence should be verified using current guidelines.
• Pediatric patients: The Twisthaler 110 mcg is approved for ages 4+, while HFA 50 mcg is approved for ages 5+. If the Twisthaler becomes unavailable for a 4-year-old, the HFA is not an approved substitute.
• Device technique: Patients switching from a Twisthaler (breath-actuated dry powder) to an HFA (press-and-breathe aerosol) will need device education. Consider the QVAR RediHaler (breath-actuated HFA) as an alternative for patients who have difficulty with coordination.

Dose Equivalence Table

When switching patients to an alternative ICS, approximate dose equivalence (based on NAEPP/GINA guidelines) should be used:

• Mometasone 220 mcg/day ≈ Fluticasone propionate 250 mcg/day ≈ Budesonide 400 mcg/day ≈ Beclomethasone 160 mcg/day ≈ Ciclesonide 160 mcg/day (medium dose)
• Mometasone 440 mcg/day ≈ Fluticasone propionate 500 mcg/day ≈ Budesonide 800 mcg/day ≈ Beclomethasone 320 mcg/day ≈ Ciclesonide 320 mcg/day (high dose)

These are approximations. Individual patient response may vary, and clinical follow-up within 2–4 weeks of a switch is recommended to assess asthma control.

Current Availability Picture

As of early 2026:

• Asmanex HFA 200 mcg: Most consistently available
• Asmanex HFA 100 mcg: Intermittently available; improving
• Asmanex HFA 50 mcg: Limited availability
• Asmanex Twisthaler 110 mcg: Available at some pharmacies
• Asmanex Twisthaler 220 mcg: Increasingly difficult to find; possible discontinuation

Availability is dynamic and varies significantly by region and pharmacy. A real-time availability tool like Medfinder for Providers can help identify pharmacies with current stock before sending a prescription.

Cost and Access Landscape

Asmanex remains brand-only with no FDA-approved generic as of March 2026. This impacts cost and access:

• Average cash price: $190–$300+ per inhaler
• GoodRx coupon price: As low as $98 (HFA) or $127 (Twisthaler)
• Insurance coverage: Typically Tier 2–3 on commercial plans; Tier 3 on Medicare Part D. Some plans require step therapy (trial of generic fluticasone or QVAR first) or prior authorization.
• Organon Savings Card: Copay as low as $15 for commercially insured patients (not available for government insurance)
• Patient Assistance: Organon Access Program for uninsured/underinsured patients (1-877-264-2454)

Recommended Therapeutic Alternatives

When Asmanex is unavailable, the following ICS alternatives are recommended based on current evidence and availability:

1. Generic fluticasone propionate — Most widely available and affordable ICS option post-Flovent discontinuation. Available in HFA and Diskus (DPI) forms. First-line substitution for most patients.
2. Beclomethasone (QVAR RediHaler) — Breath-actuated HFA; good option for patients who had difficulty with the Twisthaler or standard press-and-breathe MDIs. Brand-only.
3. Budesonide (Pulmicort Flexhaler/Respules) — DPI (Flexhaler) or nebulizer solution (Respules). Generic nebulizer solution available. Note: Flexhaler 90 mcg and some Respules presentations have also experienced shortages.
4. Ciclesonide (Alvesco) — Prodrug activated in the lungs; lower risk of oropharyngeal side effects. Good option for patients with ICS-related thrush or dysphonia. Brand-only; ages 12+.

For a patient-facing resource on alternatives, you can share: Alternatives to Asmanex.

Tools and Resources for Providers

• Medfinder for Providers — Check real-time pharmacy availability before prescribing. Helps route prescriptions to pharmacies that actually have the medication in stock.
• ASHP Drug Shortages — Monitor shortage status updates at ashp.org/drug-shortages
• FDA Drug Shortages Database — accessdata.fda.gov/scripts/drugshortages
• Organon Medical Information — 1-844-674-3200 for clinical questions about Asmanex supply and alternatives

Looking Ahead

The ICS market is likely to remain constrained through at least mid-2026 as the ripple effects of the Flovent discontinuation continue to work through the supply chain. Providers should:

• Proactively review panels for patients on Asmanex and develop contingency plans
• Educate patients about the possibility of needing to switch and the importance of not missing doses
• Document alternative ICS preferences in the medical record to streamline future substitutions
• Use availability tools to confirm stock before sending prescriptions

For a patient-facing guide to help your patients navigate the shortage, share: How to Find Asmanex in Stock Near You.

Final Thoughts

The Asmanex shortage is a direct consequence of market disruption in the ICS class. While challenging, it's manageable with proactive planning, clear therapeutic substitution protocols, and patient communication. The patients most at risk are those who lose continuity of their controller medication — and that's preventable with the right approach.